ReviewNuclear receptor signaling2007
Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR.
Review in Nuclear receptor signaling, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 80 citations in OpenAlex.
- Expression of estrogen receptors, PELP1, and SRC in human spermatozoa and their associations with semen quality.Human cell · 2023Article
- SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.Breast cancer research : BCR · 2022Article
- Clinical Evaluation of Proline, Glutamic acid, and Leucine-Rich Protein 1 Expression in Astrocytomas and Correlations with the Proliferation Marker Ki-67.Journal of molecular neuroscience : MN · 2021Article
- PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathway.Molecular carcinogenesis · 2020Article
- Ginsenoside Rg1 activates ligand-independent estrogenic effects via rapid estrogen receptor signaling pathway.Journal of ginseng research · 2019Article
- The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes.Cancer research and treatment · 2019Article
- Article
- Review
- DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERα-positive breast cancer cells.Breast cancer research and treatment · 2015Article
- PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.Cancer research · 2014Article
- Proline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA damage response.Cell death and differentiation · 2014Article
- Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.Oncogene · 2014Article
- Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.Molecular cancer therapeutics · 2014Article
- PELP1 oncogenic functions involve alternative splicing via PRMT6.Molecular oncology · 2014Article
- PELP1 suppression inhibits colorectal cancer through c-Src downregulation.Oxidative medicine and cellular longevity · 2014Article
- Increased PELP1 expression in rat periodontal ligament tissue in response to estrogens treatment.Journal of molecular histology · 2013Article
- The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer.BMC cancer · 2013Article
- Temporal expression of Pelp1 during proliferation and osteogenic differentiation of rat bone marrow mesenchymal stem cells.PloS one · 2013Article
- Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer.Nature communications · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Proline-, glutamic acid-, and leucine-rich protein (PELP)1, also known as modulator of nongenomic actions of the estrogen receptor (MNAR), is a novel nuclear receptor coregulator with a multitude of functions. PELP1/MNAR serves as a scaffolding protein that couples various signaling complexes with nuclear receptors and participates in genomic and nongenomic functions. Recent data suggest that PELP1/MNAR expression is deregulated in several cancers, including breast, endometrial, prostate, and ovarian cancer, and that PELP1/MNAR interacts with several oncogenes. In this review, we summarize the emerging biological properties and functions of PELP1/MNAR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.